Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Background: Baricitinib is an oral janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and is approved in Europe for use in adults with moderately-to-severely active RA and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drug (csDMARD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clinicoecon Outcomes Res
Asıl Yazarlar: Schlueter, Max, Finn, Elaine, Díaz, Silvia, Dilla, Tatiana, Inciarte-Mundo, José, Fakhouri, Walid
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6560251/
https://ncbi.nlm.nih.gov/pubmed/31239736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S201621
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller